Consistently, in the results of the phase II CITYSCAPE trial assessing the efficacy of tiragolumab in combination with atezolizumab, the simultaneous targeting of TIGIT and PD-L1 significantly enhanced survival in NSCLC patients, with a safety profile similar to that of atezolizumab alone [110]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.